Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
Status:
Completed
Trial end date:
2020-03-03
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of
single-ascending intravenous (IV) infusions of BIIB076 in healthy volunteers and participants
with Alzheimer's disease (AD). A secondary objective of the study for both healthy volunteers
and participants with AD is to assess the serum pharmacokinetic(s) (PK) profile of BIIB076
after single-dose administration. Another secondary objective is to evaluate the
immunogenicity of BIIB076 in serum after single-dose administration.